Orphanet: Búsqueda simple
x

Búsqueda de un ensayo clínico

* (*) Campo obligatorio

18 Resultado(s)

Ensayo clínico en reclutamiento = Ensayo clínico en reclutamiento
; Ensayos clínico en curso = Ensayos clínico en curso 
; Financiado por un miembro del IRDiRC =

Ensayo(s) clínico(s) nacional(es)

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658 (morpholino oligomer directed against exon 51)
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Ensayo clínico en reclutamiento
Ensayos clínico en curso 
Financiado por un miembro del IRDiRCA Phase III Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Ensayos clínico en curso 
An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy (phase III) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

FOR-DMD: Duchenne muscular dystrophy: doubleblind randomized trial to find optimum steroid regimen (phase III) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Ensayos clínico en curso 
An Open-Label Study for Previously Treated Ataluren (PTC124®) Patients with Nonsense Mutation Dystrophinopathy (phase III) - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Ensayos clínico en curso 
PTC124-GD-007-DMD: A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy - UK
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Ensayo clínico en reclutamiento
Ensayos clínico en curso 
Phase II Feasibility Study of the Efficacy and Acceptability of a Low Residue Diet in Adult Patients With Mitochondrial Disease
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Ensayo(s) clínico(s) multinacional(es)

BELGICA

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Financiado por un miembro del IRDiRCSCOPE-DMD: Consortium for Products across Europe in Duchenne Muscular Dystrophy
European Commission
DG Research - Directorate General for Research

REINO UNIDO (EL)

Tyne & Wear
NEWCASTLE UPON TYNE

Financiado por un miembro del IRDiRCSCOPE-DMD: Consortium for Products across Europe in Duchenne Muscular Dystrophy
Newcastle upon Tyne Hospitals NHS Trust
John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine